Nothing Special   »   [go: up one dir, main page]

SG10201408392PA - Methods of determining patient response by measurement of her-3 - Google Patents

Methods of determining patient response by measurement of her-3

Info

Publication number
SG10201408392PA
SG10201408392PA SG10201408392PA SG10201408392PA SG10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA
Authority
SG
Singapore
Prior art keywords
methods
measurement
patient response
determining patient
determining
Prior art date
Application number
SG10201408392PA
Inventor
Michael Bates
Jennifer W Cook
Gundo Diedrich
Laurie Goodman
Ali Mukherjee
Gordon Parry
Jeff Sperinde
Stephen John Williams
Original Assignee
Lab Corp America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Corp America Holdings filed Critical Lab Corp America Holdings
Publication of SG10201408392PA publication Critical patent/SG10201408392PA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

METHODS OF DETERMINING PATIENT RESPONSE BY MEASUREMENT OF The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3. FIGURE 1 69
SG10201408392PA 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3 SG10201408392PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US17663009P 2009-05-08 2009-05-08
US18796209P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
SG10201408392PA true SG10201408392PA (en) 2015-01-29

Family

ID=42340114

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201408392PA SG10201408392PA (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3
SG2011050994A SG172983A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011050994A SG172983A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Country Status (12)

Country Link
US (4) US8349574B2 (en)
EP (1) EP2387711B1 (en)
JP (1) JP5746051B2 (en)
KR (1) KR20110120891A (en)
CN (1) CN102460152B (en)
AU (1) AU2010204583A1 (en)
BR (1) BRPI1007321A2 (en)
CA (1) CA2749846C (en)
ES (1) ES2535723T3 (en)
IL (1) IL214072A (en)
SG (2) SG10201408392PA (en)
WO (1) WO2010083470A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
WO2009070772A1 (en) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
US10416162B2 (en) * 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
CA2764386C (en) * 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
US11401344B2 (en) * 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
AU2010204576A1 (en) * 2009-01-15 2011-09-01 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of HER-2 expression
EP2430047B1 (en) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010306862B2 (en) 2009-10-13 2015-08-27 Bruker Spatial Biology, Inc. Protein detection via nanoreporters
RU2560583C2 (en) 2009-12-22 2015-08-20 Рош Гликарт Аг Antibodies to her3 and application thereof
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
RU2638806C2 (en) * 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
EP2710379B1 (en) * 2011-05-19 2016-12-14 Laboratory Corporation of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
CA2842860A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
PL2972193T3 (en) 2013-03-13 2020-08-24 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2014165855A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
ES2669201T3 (en) 2013-10-04 2018-05-24 Roche Diagnostics Gmbh Antibodies that specifically bind HER3
JP6771385B2 (en) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ Bispecific antibody and pharmaceutical composition
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
EP3325650B1 (en) 2015-07-17 2024-01-03 Nanostring Technologies, Inc. Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
EP3325649B1 (en) 2015-07-17 2024-01-03 Nanostring Technologies, Inc. Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
BR112018008068A2 (en) 2015-10-23 2018-11-13 Merus N.V. binding molecules that inhibit cancer growth
CA3016914C (en) * 2016-03-15 2019-08-27 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
BR112019020507A2 (en) 2017-03-31 2020-08-04 Merus N.V. erbb-2 targeting agent and a bispecific antibody with antigen binding sites that bind an epitope to an extracellular part of erbb-2 and erbb-3 for treating an individual with an erbb-2, erbb-2 / positive tumor erbb-3
CN110650752A (en) 2017-03-31 2020-01-03 美勒斯公司 ErbB-2 and ErbB3 binding bispecific antibodies for treating cells with NRG1 fusion gene
US11773170B2 (en) 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
CN112154216A (en) 2018-02-12 2020-12-29 纳米线科技公司 Biomolecule probes and methods for detecting gene and protein expression

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5117165B1 (en) 1973-12-27 1976-05-31
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
AU636110B2 (en) 1988-06-08 1993-04-22 Nichols Institute Diagnostics Assays utilizing sensitizer-induced production of detectable signal
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0484027B1 (en) 1990-11-02 1996-12-18 Zeneca Limited Polysubstituted phthalocyanines
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
EP0653066B1 (en) 1992-07-31 1998-01-28 BEHRINGWERKE Aktiengesellschaft Photoactivatable chemiluminescent matrices
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
DE69530763T2 (en) * 1994-03-29 2004-02-26 Celltech Therapeutics Ltd., Slough ANTIBODIES AGAINST E-SELECTECT
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
SE9601676D0 (en) 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US20040248150A1 (en) 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6682887B1 (en) * 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US6673550B2 (en) * 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US7037654B2 (en) * 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US20030092012A1 (en) 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
JP5623681B2 (en) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド Treatment with anti-ErbB2 antibody
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
AU2951801A (en) * 2000-01-12 2001-07-24 Ventana Medical Systems, Inc. Method for quantitating a protein by image analysis
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
MY133839A (en) 2000-03-14 2007-11-30 Shell Int Research Process for the carbonylation of pentenenitrile
GB0007911D0 (en) 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US20030207300A1 (en) 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
ES2370232T3 (en) 2000-05-04 2011-12-13 Siemens Healthcare Diagnostics Products Gmbh PROCEDURE FOR THE DETECTION OF MULTIPLE ANALYTICS.
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
JP2004511223A (en) 2000-08-08 2004-04-15 アクララ　バイオサイエンシーズ，　インコーポレイテッド Multiplexed enzyme assays
AU2001280222A1 (en) 2000-08-19 2002-03-04 Sung-Cheol Kim Communication line separator
ES2394293T3 (en) 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vaccine against cancers that are associated with the HER-2 / neu oncogene
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
EP1506399A2 (en) 2001-05-21 2005-02-16 Aclara BioSciences, Inc. Methods and compositions for analyzing proteins
US7041459B2 (en) * 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
AU2002344221A1 (en) 2001-05-26 2002-12-09 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
AU2002316577A1 (en) 2001-07-09 2003-01-29 Aclara Biosciences, Inc. Cell-screening assay and composition
WO2003055439A2 (en) 2001-07-18 2003-07-10 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
AU2002319613A1 (en) 2001-07-19 2003-03-03 Signet Laboratories, Inc. Human tissue specific drug screening procedure
GB2378245A (en) 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
CA2456732C (en) 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
EP1434535A1 (en) 2001-10-12 2004-07-07 Gyne Ideas Limited Biomaterial comprising microfeatures
WO2003033741A1 (en) 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) * 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
WO2003042699A1 (en) 2001-11-09 2003-05-22 Aclara Biosciences Inc. Tagged microparticle compositions and methods
WO2003042657A2 (en) 2001-11-09 2003-05-22 Aclara Biosciences Inc. Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
WO2003042658A2 (en) 2001-11-09 2003-05-22 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US7341362B2 (en) 2001-12-18 2008-03-11 Monogram Biosciences, Inc. Photoactivation device and method
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
BR0307994A (en) * 2002-02-26 2004-12-07 Sigma Tau Ind Farmaceuti Human antitenascin monoclonal antibody
CA2475516A1 (en) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
EP2258872B1 (en) 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003226195A1 (en) 2002-04-02 2003-10-20 Monogram Biosciences, Inc. Multiplexed assays using electrophoretically separated molecular tags
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20090111127A1 (en) 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040175765A1 (en) 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
ATE535254T1 (en) * 2002-07-15 2011-12-15 Genentech Inc TREATING CANCER WITH THE ANTI-ERBB2 ANTIBODY RHUMAB 2C4
ATE442589T1 (en) 2002-07-25 2009-09-15 Aclara Biosciences Inc DETECTION OF RECEPTOR OLIGOMERIZATION
AU2003249050A1 (en) 2002-07-26 2004-02-16 Monogram Biosciences, Inc. Lipophilic electrophoretic probes
US20040091850A1 (en) 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
EP1573061A4 (en) 2002-12-18 2006-03-08 Aclara Biosciences Inc Multiplexed immunohistochemical assays using molecular tags
WO2004068116A2 (en) 2003-01-17 2004-08-12 Aclara Biosciences, Inc. Receptor deorphanization using tagged molecular libraries
JP2006521821A (en) 2003-04-01 2006-09-28 モノグラム バイオサイエンシズ，インコーポレーテッド Surface receptor complex as a biomarker
US20100291594A1 (en) 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
JP2007502417A (en) 2003-08-11 2007-02-08 モノグラム バイオサイエンシズ，インコーポレーテッド Detection and characterization of molecular complexes
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp Biomarkers in cancer
US20050106571A1 (en) 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
EP1681983A4 (en) 2003-10-14 2008-12-10 Monogram Biosciences Inc Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
US20050130246A1 (en) 2003-10-27 2005-06-16 Hossein Salimi-Moosavi Detecting human anti-therapeutic antibodies
EP1674111B1 (en) 2004-07-09 2010-11-03 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
DE602005023529D1 (en) 2004-11-03 2010-10-21 Iris Molecular Diagnostics Inc HOMOGENEOUS DETECTION OF ANALYTES
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
WO2006068640A1 (en) * 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Protein phosphorylation in egfr-signaling pathways
WO2006084018A2 (en) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Methods for determining responsiveness to cancer therapy
US20060177448A1 (en) * 2005-02-09 2006-08-10 Genentech, Inc. Inhibiting HER2 shedding with matrix metalloprotease antagonists
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (en) 2005-09-09 2010-04-28 上海张江生物技术有限公司 Immunodiagnosis reagent kit for breast cancer and test slip
WO2007041502A2 (en) * 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP5117165B2 (en) 2007-11-09 2013-01-09 花王株式会社 Method for producing oil-in-water emulsion composition
WO2009070772A1 (en) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
CN101230390A (en) 2007-12-07 2008-07-30 湖北大学 Gene chip for gynecologic malignant tumor early screening and detection method thereof
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2342646B1 (en) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron METHOD OF DIAGNOSIS OF CANCERES THAT EXPRESS THE RECEIVER HER-2 OR ITS TRUNCATED VARIANTS.
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CA2764386C (en) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
AU2010204576A1 (en) 2009-01-15 2011-09-01 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of HER-2 expression

Also Published As

Publication number Publication date
CN102460152B (en) 2014-11-26
AU2010204583A1 (en) 2011-08-25
US8349574B2 (en) 2013-01-08
US20130071859A1 (en) 2013-03-21
EP2387711A4 (en) 2012-07-18
WO2010083470A1 (en) 2010-07-22
CN102460152A (en) 2012-05-16
US20180164319A1 (en) 2018-06-14
KR20110120891A (en) 2011-11-04
IL214072A (en) 2016-08-31
US20100210034A1 (en) 2010-08-19
JP5746051B2 (en) 2015-07-08
JP2012515226A (en) 2012-07-05
IL214072A0 (en) 2011-08-31
SG172983A1 (en) 2011-08-29
AU2010204583A2 (en) 2011-09-01
BRPI1007321A2 (en) 2018-07-10
CA2749846A1 (en) 2010-07-22
US20160061839A1 (en) 2016-03-03
US9110066B2 (en) 2015-08-18
CA2749846C (en) 2018-08-07
EP2387711A1 (en) 2011-11-23
ES2535723T3 (en) 2015-05-14
EP2387711B1 (en) 2015-04-22
US10775382B2 (en) 2020-09-15
US9766242B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
HK1202925A1 (en) Test sensor for determining analyte concentration in fluid sample
BR112012030788A2 (en) monoclonal antibody detection methods for enzymes conferring resistance to 2,4-dichlorophenoxyacetic acid in plants
BRPI0915619A2 (en) methods for determining a probability that a subject has contributed genetic material to the genetic material test sample, to characterize genetic material test sample, and to determine whether a person of interest has contributed genetic material to a genetic material test sample , genetic material test sample analysis kit, and system to determine if a subject has contributed genetic material to a sample
WO2014074835A3 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
PL2021794T3 (en) Use of protein s100a 12 as a marker for colorectal cancer
EP2449129A4 (en) Methods of determining the presence and/or concentration of an analyte in a sample
MX336109B (en) Immuno-pet imaging of antibodies and immunoconjugates and uses therefor.
HK1165001A1 (en) Method for measurement of equol in biological sample by immunoassay, kit for the measurement, and method for determination of equol production ability of subject
MX2011013915A (en) Analysis device and analysis method.
PL2040072T3 (en) Analysis system for measuring the concentration of an analyte in a bodily fluid
GB201014837D0 (en) Biomarker signatures and uses thereof
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
EP2383570A3 (en) Measuring device, measuring method, and program
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
SG10201806729VA (en) Novel assay to detect human periostin
EP2120042A4 (en) Biological specimen measurement test piece, and biological specimen measuring device
WO2010097553A3 (en) Method for diagnosing vasculitis
WO2010000467A8 (en) Asc as a marker for lung cancer
MX341181B (en) Method for testing a subject thought to be predisposed to having metastatic cancer using delta133p53beta.
EA201400571A1 (en) SPECIFIC TO TRANSRESVEROTROL ANTIBODIES AND THEIR APPLICATION